Vytorin Re-Endorsed By FDA Despite Lack Of Impact On Carotid Artery Thickness
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency offers three possible explanations for why a reduction in LDL failed to translate into a drop in cIMT.
You may also be interested in...
IMPROVEd Timing On Vytorin Outcomes Data?
Full results from the massive study will be delayed a year, but an earlier interim analysis could help resolve questions about the safety and efficacy of Merck's cholesterol drug.
IMPROVEd Timing On Vytorin Outcomes Data?
Full results from the massive study will be delayed a year, but an earlier interim analysis could help resolve questions about the safety and efficacy of Merck's cholesterol drug.
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.